Stereotactic body radiotherapy for early stage lung cancer

Abstract

Stereotactic body radiotherapy (SBRT) is an important treatment option for inoperable patients with stage I non-small cell lung cancer, especially elderly patients, the number of which is currently increasing. An impaired pulmonary function itself is not a contraindication for SBRT; however, interstitial pneumonia should be treated with care, as it is a significant risk factor for severe radiation pneumonitis after SBRT. The use of SBRT in cases of centrally located tumors also requires special care due to the potential for severe toxicity. Multi- institutional trials of SBRT have demonstrated a local control rate of 9QO and 3-year overall survival rate of 6O% among inoperable patients. Therefore, it is necessary to accumulate further evidence and develop new therapies in order to improve outcomes, reduce toxicities and expand SBRT indications.